Schaeffer's Top Stock Picks for '25

Call Players Lose Faith as Gilead Sciences, Inc. (GILD) Slides to New Lows

Long-term underperformer Gilead Sciences, Inc. (GILD) hit a fresh two-year low

Jan 24, 2017 at 2:51 PM
facebook X logo linkedin


Drug stock Gilead Sciences, Inc. (NASDAQ:GILD) is down today, last seen 0.9% lower at $70.01, and earlier hit a new two-year low of $69.78. The stock has spent the better part of the last year succumbing to pressure from its 20-week moving average, and the shares recently gave up a foothold at the $72 mark, which had kept losses in check since October. As GILD continues its journey downward, it appears some options traders may be losing faith.

GILD calls are changing hands at three times the expected intraday rate, with volume running in the 98th annual percentile. Responsible for a large portion of today's action, however, are two large trades made by call players rolling down their bets, according to Trade-Alert. Specifically, it appears one trader rolled a block of 10,000 May 75 calls down to the 70 strike, while another rolled her May 85 calls down to the 77.50 strike.

Rolling down a position simply means closing out a higher strike, while simultaneously opening a position at a lower one with the same expiration. Call players rolling down out-of-the-money positions are likely looking to limit their total risk amid tempered expectations. To put it another way, today's traders may have simply lost faith in shares of the drugmaker rallying as far as previously anticipated over the coming months.

In fact, options traders have shown signs of growing skepticism in recent weeks. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), GILD now holds a 10-day put/call volume ratio of 0.61 -- higher than 93% of all other readings from the past year. Two weeks ago, the comparable metric was a much less put-heavy 0.41.

Conversely, short interest on GILD dropped by more than 15% during the two most recent reporting periods, and now represents just 1% of the equity's total float. What's more, 12 out of 20 analysts rate the biotech stock a "buy" or better, while not one calls it a "sell." Suffice it to say, if sentiment here shifts bearishly as it has in the options pits, Gilead Sciences, Inc. (NASDAQ:GILD) could explore lower lows.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.
 
 

Which of These SUB-$5 Stocks Could 26x From Here? (AD)

He called a rare 11x on Tesla…

Then he called a 26x on Workhorse…

Then an even rarer 35x on Nio Inc…

Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.

They’re trading for less than $5 right now.

But thanks to Elon & Trump’s new alliance…

They could be off to the races in Trump’s first 100 days.

And right now for a limited time…

You can get the names & tickers for just $1 here. (AD)

10 Stock Picks FREE
 
 

Featured Articles from Trusted Partners:

🚀 One Stock Pick Could Change Everything in 2025
What if one stock pick could define your success next year? Get 10 expert-vetted stocks set for 2025—plus 5 bonus picks to watch now. Get the Report →

🆕 New Options Need New Trading Strategies
Zero-DTE options are the newest (and hottest) options to trade.  Professional traders have rushed into the market and are making a mint.  Don’t get left behind - learn all about these options, how to trade them, market setups to profit from, plus much more. Download now →

👀 Revealed: 3 Defensive Stocks for Your Portfolio
Worried about the market? This free report reveals 3 under-the-radar defensive stocks for uncertain times in any kind of economy.

 

 
 

FREE Report Download

 

Follow us on X, Follow us on Twitter